We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Exelixis, Inc. (NASDAQ:EXEL) stands against other best ...

Exelixis' future depends on trial outcomes and patent risks. Find out why EXEL stock is a "Sell" despite cabozantinib's ...

It has been about a month since the last earnings report for Exelixis (EXEL). Shares have added about 13.4% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Over the last 7 days, the United States market has experienced a 2.5% ...

Exelixis stock opened at $36.65 on Thursday. The firm has a 50 day moving average of $35.36 and a 200 day moving average of $32.48. The firm has a market capitalization of $10.26 billion, a price ...

RBC Capital raised the firm’s price target on Exelixis (EXEL) to $40 from $38 and keeps an Outperform rating on the shares. The firm notes ...

Genitourinary Cancer Symposium 2025, held on 13-15 February, final results from the randomised, multicentre, double-blind, ...

Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 5.6% in the ...

In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Exelixis (EXEL – Research Report). The ...

Renaissance Technologies' 13F reveals shifts in a $67.6B portfolio with notable changes in Palantir, Novo Nordisk, and NVIDIA ...

It has been about a month since the last earnings report for Exelixis (EXEL). Shares have added about 13.4% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...